AU
UK
CA
NZ
IND
US
Cedar Woods Properties (ASX:CWP) First Half 2023 Results Key Financial Results Revenue: AU$152.3m (down 13% from 1H 2022). Net income: AU$9.06m (down 36% from 1H 2022). Profit margin: 6.0% (down from 8.1% in 1H 2022). The decrease in margin was driven by lower revenue. …
Redx Pharma and Jounce Therapeutics Inc (NASDAQ: JNCE) agreed to merge via a proposed all-share transaction. Redx is a clinical-stage biotechnology company focused on discovering and developing small molecule, targeted therapeutics for cancer and fibrotic diseases and cancer-associated fibrosis. The combined group's highest priority …
TORONTO, Feb. 23, 2023 /CNW/ - TD Asset Management Inc. ("TDAM"), the manager of the TD Exchange-Traded Funds listed below (collectively, the "TD ETFs") announced that, effective today, the risk rating for each of the TD ETFs listed in the table below has changed. …
TORONTO, Feb. 23, 2023 /CNW/ - Mackenzie Investments today announced the February 2023 monthly cash distributions for its Exchange Traded Funds ("ETFs") listed below that trade on the Toronto Stock Exchange (TSX) and Aequitas NEO Exchange. Unitholders of record on March 2, 2023 will …
New ETFs provide investors with five different exposures to S&P Dividend Aristocrats Indexes designed to offer solid dividends with an ESG overlay TORONTO, Feb. 23, 2023 /PRNewswire/ -- Invesco Canada Ltd. ("Invesco") today announced the launch of five new exchange-traded funds (ETFs) that will …
UPL's Greenhouse Gas (GHG) emissions reduction commitments approved by Science Based Targets initiative (SBTi) in-line with climate science UPL will make significant reductions to its GHG emissions by 2034 in-line with SBTi recognized well-below 2°C global temperature rise trajectory CEO Jai Shroff describes commitment …
(Adds details on value of combined company, stock spilt plans and ownership details) Feb 23 (Reuters) - British biotech firm Redx Pharma plc and U.S.-based Jounce Therapeutics Inc will merge to create a $425 million entity specialised in treating cancer and fibrotic disease. Redx …
Jounce Therapeutics, Inc. Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include …
With its stock down 7.1% over the past three months, it is easy to disregard Primary Health Properties (LON:PHP). However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. In this article, we …
TORONTO, Feb. 23, 2023 /CNW/ - Superior Gold Inc. ("Superior" or the "Company") (TSXV: SGI) (OTCQX: SUPGF) announces that it has entered into a definitive agreement (the "Agreement") pursuant to which Catalyst Metals Limited ("Catalyst") (ASX: CYL) will acquire all of the issued and …
Please wait processing your request...